Roche Holding : Feedback call EASD
>Profils cliniques différenciés de CT-388 et CT-996 non validés à ce stade - Dans le cadre du congrès de l’EASD qui s’est tenu la semaine dernière, Roche a présenté de nouvelles données cliniques de phase 1 pour ses deux actifs phares dans l’obésité, dont nous retenons les points suivants :CT-388 (GIP/GLP-1 ; injection hebdomadaire) : les données à 24 semaines montrent une réduction de poids de 18.9% à la dose la plus forte ce qui positionne CT-388 parmi les pr...Roche Holding is a healthcare company. Co. operates in two Divisions, Pharmaceuticals and Diagnostics. Co.'s pharmaceuticals division is comprised of two business segments Roche Pharmaceuticals and Chugai. Co.'s pharmaceuticals division provides therapies including Cotellic, in combination with Zelboraf for advanced melanoma, and Alecensa for a specific type of lung cancer. Co.'s diagnostics division consists of four business areas: Diabetes Care, Molecular Diagnostics, Professional Diagnostics and Tissue Diagnostics. Co.'s diagnostics division provides in vitro diagnostic tests, used by healthcare providers to screen, diagnose and monitor therapies.
Oddo Securities provides securities brokerage and research services. The company offers equity, economic, and derivatives research and credit analysis services. It focuses on insurance, automotive, building materials, pharmaceuticals, telecommunications, information technology, and agri-food industries.
Unfortunately, this report is not available for the investor type or country you selected.
Browse all ResearchPool reportsReport is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.